Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems

Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems

Abstract XPO1 has recently emerged as a viable treatment target for solid malignancies, including glioblastoma (GBM), the most common primary malignant brain tumor in adults. However, given that tumors become commonly resistant to single treatments, the identification of combination therapies is cri...

Full description

Bibliographic Details
Main Authors: Enyuan Shang, Yiru Zhang, Chang Shu, Chiaki Tsuge Ishida, Elena Bianchetti, Mike-Andrew Westhoff, Georg Karpel-Massler, Markus D. Siegelin
Format: Article
Language:English
Published: Nature Portfolio 2018-10-01
Series:Scientific Reports
Subjects:
Selinexor
XPO1 Inhibition
Patient-derived Xenograft Models
Cultured Glioblastoma Cells
Glial Brain Tumors
Online Access:https://doi.org/10.1038/s41598-018-33784-2

Internet

https://doi.org/10.1038/s41598-018-33784-2

Similar Items